Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

Back

Immunoreactivity to Cetuximab in Cancer Patients

NCT00896896·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Vanderbilt-Ingram Cancer Center

With

National Cancer Institute (NCI)

OBJECTIVES: * To examine serum samples from patients with head and neck cancer or advanced colorectal cancer previously treated with cetuximab for the presence of antibodies against cetuximab. OUTLINE: Serum samples are examined by immunoreactivity screening of IgE, IgG, IgA, and IgM antibodies and complement reaction.

Age

18–75

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

DISEASE CHARACTERISTICS:
Diagnosis of one of the following:
* Head and neck cancer
* Advanced colorectal cancer
Previously treated with cetuximab
Serum samples available from patients enrolled in one of the following clinical trials:
* VU-VICC-GI-0410 (colorectal cancer)
* VU-VICC-GI-0622 (colorectal cancer)
* VU-VICC-HN-0356 (head and neck cancer)
PATIENT CHARACTERISTICS:
Not specified
PRIOR CONCURRENT THERAPY:
See Disease Characteristics

The record

StatusCompleted

PhaseNo phase

Taking part538

StartedNov 2006

UpdatedApr 2, 2013

Conditions

Colorectal Cancer Head and Neck Cancer

Clareo Health | Immunoreactivity to Cetuximab in Cancer Patients